Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 6/20 | 0.67 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.67 |
| ▸ | LTA4H | P09960 | 6/20 | 0.65 |
| ▸ | LAP3 | P28838 | 1/20 | 0.59 |
| ▸ | PPARG | P37231 | 2/20 | 0.56 |
| ▸ | PPARA | Q07869 | 2/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.53 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5352880 | 0.90 | LTA4H (0.62) | FFAR1FFAR4LTA4HLAP3PPARG | |
| SCHEMBL289033 | 0.86 | LTA4H (0.67) | FFAR1FFAR4LTA4HLAP3PPARG | |
| SCHEMBL5888154 | 0.86 | LTA4H (0.67) | FFAR1FFAR4LTA4HLAP3PPARG | |
| SCHEMBL288473 | 0.85 | CPA3 (0.62) | FFAR1LTA4H | |
| SCHEMBL157500 | 0.85 | CPA3 (0.62) | FFAR1LTA4H | |
| SCHEMBL5767750 | 0.85 | CPA3 (0.62) | FFAR1LTA4H | |
| SCHEMBL758429 | 0.83 | CYSLTR2 (0.67) | FFAR1FFAR4LTA4HPPARGPPARA | |
| SCHEMBL5358938 | 0.82 | LTA4H (0.74) | FFAR1FFAR4LTA4HLAP3PPARG | |
| SCHEMBL2032141 | 0.82 | LTA4H (0.74) | FFAR1FFAR4LTA4HLAP3PPARG | |
| SCHEMBL2027392 | 0.82 | LTA4H (0.74) | FFAR1FFAR4LTA4HLAP3PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017481-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2018-07-10 | — | — | US | claimed |
| EP-2836485-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2018-01-10 | — | — | EP | claimed |
| EP-2499148-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2017-01-18 | — | — | EP | claimed |
| US-9512139-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2016-12-06 | — | — | US | claimed |
| US-20150051183-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2015-02-19 | — | — | US | claimed |
| EP-2836485-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | Polyphor Ag (CH) | 2015-02-18 | — | — | EP | claimed |
| EP-2462147-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2014-11-12 | — | — | EP | claimed |
| WO-2013139697-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2013-09-26 | — | — | WO | claimed |
| US-20120270881-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2012-10-25 | — | — | US | claimed |
| EP-2499148-A2 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | Polyphor Ag (CH) | 2012-09-19 | — | — | EP | claimed |
| WO-2011014973-A2 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2011-02-10 | — | — | WO | claimed |
| EP-3087094-B1 | BETA-HAIRPIN PEPTIDOMIMETICS AS SELECTIVE ELASTASE INHIBITORS | POLYPHOR AG (CH) | 2022-06-01 | — | — | EP | disclosed |
| US-10273267-B2 | Beta-hairpin peptidomimetics as selective elastase inhibitors | POLYPHOR AG (CH) | 2019-04-30 | — | — | US | disclosed |
| US-10017481-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2018-07-10 | — | — | US | disclosed |
| EP-2836485-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2018-01-10 | — | — | EP | disclosed |
| US-8865656-B2 | Beta-hairpin peptidomimetics having CXCR4 antagonizing activity | POLYPHOR AG (CH) | 2014-10-21 | — | — | US | disclosed |
| WO-2013139697-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2013-09-26 | — | — | WO | disclosed |
| US-20120135942-A1 | BETA-HAIRPIN PEPTIDOMIMETICS | POLYPHOR AG (CH) | 2012-05-31 | — | — | US | disclosed |
| EP-2427476-A1 | BETA-HAIRPIN PEPTIDOMIMETICS HAVING CXCR4 ANTAGONIZING ACTIVITY | Polyphor Ag (CH) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010127704-A1 | BETA-HAIRPIN PEPTIDOMIMETICS HAVING CXCR4 ANTAGONIZING ACTIVITY | POLYPHOR AG (CH) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135942-A1 | BETA-HAIRPIN PEPTIDOMIMETICS | CXCR4, CXCL12, CXCR6 | FFAR1 2878/4885FFAR4 2271/4885LTA4H 2759/4885 |
| US-10273267-B2 | Beta-hairpin peptidomimetics as selective elastase inhibitors | SERPINB1, ELANE, XPNPEP1 | FFAR1 4652/4885FFAR4 4360/4885LTA4H 304/4885 |
| US-10017481-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | CTSE, CTSB, CTSS | FFAR1 310/4885FFAR4 434/4885LTA4H 51/4885 |
| US-20120270881-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | KCNB1, KCNAB1, KCNMB1 | FFAR1 265/4885FFAR4 427/4885LTA4H 2249/4885 |
| US-20150051183-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | CTSE, CTSB, CTSS | FFAR1 310/4885FFAR4 434/4885LTA4H 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.